Cleerly Stock
Heart Disease Diagnosis Solutions
Sign up today and learn more about Cleerly Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Cleerly Stock
Cleerly is a healthcare company whose mission is to create digital care pathways to prevent heart attacks. The company develops a new standard for coronary artery disease by integrating quality clinical science with the latest-generation AI to offer actionable clinical insights to every stakeholder in the heart care pathway. Through these data-driven solutions, the company aims to provide a comprehensive solution for cardiovascular disease evaluation that offers value to the healthcare system and improves heart health for patients at risk of heart attacks.
Cleerly is headquartered in New York, NY, and was founded in 2017. Notable investors include Fidelity Management and Research, Novartis, and T. Rowe Price.
Investors
Breyer Capital
Oscar Health, Circle, Shield AI, Stash Financial, Prosper Marketplace, C3 IoT, Grammarly, Etsy, Cleerly, Mark43
Cigna Ventures
DigiTx Partners
Fidelity Management and Research
MasterClass, Wheels Up, Rent the Runway, Somatus, ACV, The Honest Company, Cleerly, Oportun, 10X Genomics, MNTN
Fidelity Management and Research Company
goPuff, Nuro, Bolt, Caris Life Sciences, Relativity Space, Deliveroo, Farmers Business Network, Checkr, ASAPP, Freenome
General Catalyst Partners
Snap, Jet, Stripe, Anduril Industries, Devoted Health, Lacework, Relativity Space, Oscar Health, Circle, Hopin
LRVHealth
New Leaf Venture Partners
Novartis
Sands Capital Ventures
AppDynamics, BigBasket, DoorDash, UiPath, Scopely, Snyk, DataRobot, DocuSign, Upgrade, StockX
T. Rowe Price
One97, Flipkart, WeWork, Cruise, Airbnb, Rivian, Magic Leap, Nuro, Caris Life Sciences, Vroom
Vensana Capital
Funding History
| April 2020 | $11.5M |
|---|---|
| June 2021 | $28.1M |
| June 2021 | $16.8M |
| February 2022 | $230M |
Management
Chief Executive Officer
James Min
Chief Medical Officer
James Earls
Press
businesswire - Jun, 21 2023
Cleerly Wins 2023 Artificial Intelligence Breakthrough Awardvator - Feb, 15 2023
Cleerly partners with ClearDATA to keep patient health data securebiospace - Dec, 7 2022
Cleerly Hires Udo Hoffmann, MD, MPH as Chief Scientific Officerhealthcareitnews - Nov, 6 2022
Cleerly adds tools to improve cardiovascular imaging workflowsnews - Aug, 4 2022
The 10 Biggest Rounds Of July: Xpansiv Locks In Top Spot With $400M, Cleantech Monolith Lands Huge Roundglobalventuring - Aug, 1 2022
Cleerly captures investors’ hearts in $192m series Cnews - Jul, 29 2022
The Week’s 10 Biggest Funding Rounds: Cleerly Pumps Up Large Round; Carmot Leads Biotech’s Big Weekbuiltinnyc - Jul, 26 2022
Cleerly Rakes in $192M Series C to Expand Reach, Hirecoverager - Jul, 26 2022
Cleerly raises $192 Millionbioworld - Jul, 26 2022
$192M fundraising round ‘Cleerly’ good newsbusinesswire - Jul, 25 2022
Heart Health Innovator Cleerly Closes Series C Funding Round with $192 Millionmassdevice - Jul, 25 2022
Cleerly raises $192M for AI-based software to spot atherosclerosisvator - Jul, 1 2021
Cleerly founder and CEO Jim Min on VatorNews podcastTechCrunch - Jun, 23 2021
As clinical guidelines shift, heart disease screening startup pulls in $43M Series Bfiercebiotech - Jun, 22 2021
Cleerly launches with $43M to tackle heart attacks with AI-powered imagingEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
